D-1294-2022 Class II Terminated

Recalled by Jubilant Cadista Pharmaceuticals, Inc. — Salisbury, MD

FDA drug recall D-1294-2022 was initiated by Jubilant Cadista Pharmaceuticals, Inc. on Jul 18, 2022 and is designated Class II. Reason for recall: Failed Dissolution Specifications The recall status is terminated (terminated Nov 22, 2022). Affected quantity: 28,560 bottles.

Recall details

Product Type
Drugs
Report Date
Aug 3, 2022
Initiation Date
Jul 18, 2022
Termination Date
Nov 22, 2022
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
28,560 bottles

Product description

Irbesartan Tablets, USP, 75 mg, 90- count bottle, Rx only, Manufactured by: Jubilant Generics Ltd. Roorkee- 247661, India, Marketed by: Jubilant Cadista Pharmaceuticals Inc. Salisbury, MD 21801, USA, NDC 59746-447-90

Reason for recall

Failed Dissolution Specifications

Distribution pattern

Nationwide within the United States

Code information

Lot #: IB120012A, IB120013A, IB120014A Exp. date 08/2022

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-1294-2022
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-1294-2022. Report a data issue: hello@regdatalab.com.